Who are Methadone-dexmedetomidine-ketamine combination's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methadone-dexmedetomidine-ketamine-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Methadone-dexmedetomidine-ketamine combination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Methadone-dexmedetomidine-ketamine combination (Methadone-dexmedetomidine-ketamine combination) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anesthetic combination (opioid + alpha-2 agonist + NMDA antagonist). Area: Anesthesiology.

marketed Anesthetic combination (opioid + alpha-2 agonist + NMDA antagonist) Mu opioid receptor, alpha-2 adrenergic receptor, NMDA receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Methadone-dexmedetomidine-ketamine combination (Methadone-dexmedetomidine-ketamine combination) — University of Missouri-Columbia. This combination uses methadone (opioid agonist), dexmedetomidine (alpha-2 adrenergic agonist), and ketamine (NMDA antagonist) together to produce anesthesia and analgesia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Methadone-dexmedetomidine-ketamine combination TARGET	Methadone-dexmedetomidine-ketamine combination	University of Missouri-Columbia	marketed	Anesthetic combination (opioid + alpha-2 agonist + NMDA antagonist)	Mu opioid receptor, alpha-2 adrenergic receptor, NMDA receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anesthetic combination (opioid + alpha-2 agonist + NMDA antagonist) class)

University of Missouri-Columbia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methadone-dexmedetomidine-ketamine combination — Competitive Intelligence Brief. https://druglandscape.com/ci/methadone-dexmedetomidine-ketamine-combination. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab